makena fda, fda makena, makena fda, makena approval, makena fda approval
makena fda, fda makena, makena fda, makena approval, makena fda approval
makena fda, fda makena, makena fda, makena approval, makena fda approval
6/18/2013 2:24:32 AM   KVPHQ:     KVPBQ:    
    makena fda, fda makena, makena fda, makena approval, makena fda approval  
makena fda, fda makena, makena fda, makena approval, makena fda approval



In the news


Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing
January 24, 2013

K-V Pharmaceutical Receives Court Approval of Hologic Settlement
December 28, 2012

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
December 12, 2012

K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
August 10, 2012

K-V Pharmaceutical “First Day” Motions Approved by U.S. Bankruptcy Court
August 08, 2012


Product Recall

Ask the Healthcare
Professional




A specialty pharmaceutical company committed to women's healthcare.

Headquartered in St. Louis, Missouri, KV Pharmaceutical is a specialty pharmaceutical company with a focus on women’s healthcare. Through our operations subsidiary, Ther-Rx Corporation, we develop, distribute, and support a portfolio of pharmaceutical products that healthcare providers can prescribe with confidence, and pharmacists can dispense with trust. Ther-Rx’s employees are passionately committed to advancing the health of women across all the stages of her life. Click here to learn more about us.

Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing

Single dose prescription treatment for vulvovaginal candidiasis
(yeast infections) now available on pharmacy shelves

St. Louis, January 24, 2013 – Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women1, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country.

Ther-Rx has partnered with Perrigo (www.perrigo.com) to manufacture Gynazole-1. Perrigo is a leading manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1.

Click here to view the full Company Statement.















makena fda, fda makena, makena fda, makena approval, makena fda approval
Home | Contact Us | Site Directory | Legal/Privacy | Compliance Program ©2013 KV Pharmaceutical Company. All Rights Reserved.